Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise Researchers at Washington University School of Medicine in St. Louis have ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

The test could help identify one key Alzheimer's biomarker, tau protein, before it shows up in brain. Here's what experts say ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

A complementary drug to combat Alzheimer’s disease could target a specific part of the nerve cell protein tau.

In ‘Doctored’, Charles Piller, a science journalist, details how groupthink and dishonesty steered Alzheimer’s research off ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...